Related by context. All words. (Click for frequent words.) 67 amyloid cascade 66 DDP# 65 vidofludimus 65 selective modulator 65 receptor antagonism 64 opioid receptor antagonist 64 5 HT6 receptor 63 mGluR5 inhibitors 63 Safinamide 63 selectively inhibiting 63 reuptake inhibitor 63 polycythemia vera essential thrombocythemia 63 neurogenic 63 neurotrophic 63 underlying pathophysiology 63 cardioprotective effects 62 receptor inhibitor 62 Janus kinase 62 Angiotensin II 62 hypothalamic pituitary adrenal HPA 62 Teriflunomide 62 renal fibrosis 62 PPARγ 62 pathophysiologic 62 #beta HSD1 62 fibromyalgia syndrome 62 demyelinating 62 Alzheimer Disease AD 62 antiarrhythmic drug 62 hyperalgesia 62 fibrotic disorders 62 etiologic 62 ADAMTS# 62 protein tyrosine phosphatase 1B 62 IntroductionThe 62 gastro oesophageal reflux 62 Oral Formulation 61 etiological 61 GLP 1R 61 AT1R 61 HDL Selective Delipidation 61 airway hyperresponsiveness 61 mGluR2 NAM 61 thetreatment 61 Gastroesophageal Reflux Disease 61 anticholinergic agents 61 C1 INH deficiency 61 Tolvaptan 61 receptor partial agonist 61 enkephalin 61 PD LID 61 gonadotrophin releasing hormone GnRH 61 sitaxsentan 61 analgesic effects 61 Bucindolol 61 Tyrosine Kinase Inhibitor 61 Trandolapril 61 mineralocorticoid 61 levodopa induced 61 Lubiprostone 61 Prostatitis 61 mediated inhibition 61 uricase 61 renoprotective 61 Aldosterone 61 Degarelix 61 Inhaled nitric oxide 61 Cognitive impairment 61 Almorexant 61 Enzastaurin 61 antiangiogenic agent 61 Cognitive therapy 61 virally induced 61 thromboxane A2 61 inverse agonist 61 ropinirole Requip 61 Interferon beta 61 clomipramine 61 5 HT2A receptor 61 Endothelial dysfunction 61 Pharmacologic 61 antidepressive 61 CYT# potent vascular disrupting 61 motor neuron degeneration 61 Functional neuroimaging 61 aMCI precursor 61 Brodmann Area 61 Intracerebral 61 LPA1 receptor 60 Adjunctive 60 5 HT1A receptor 60 pathophysiological effects 60 TNFα 60 5 HT4 60 upregulates 60 paraneoplastic 60 Ocrelizumab 60 Generalized Anxiety Disorder 60 NS5B polymerase 60 thromboembolic disease 60 riociguat 60 rufinamide 60 neuropsychiatric diseases 60 SYN# 60 small molecule thrombopoietin 60 melanocortin receptor 60 Gastroesophageal reflux disease 60 experimentally induced 60 MAGE A3 ASCI 60 Thiazolidinediones 60 serotonin deficiency 60 Nocturia 60 Protein Kinase C 60 idiopathic Parkinson disease 60 comorbid disorders 60 hematological parameters 60 pathogenetic 60 Valdoxan 60 selective inhibition 60 RhuDex 60 pathogenic mechanisms 60 fibrotic disease 60 postoperative ileus 60 Hyperparathyroidism 60 ziconotide 60 gene locus 60 cyclooxygenase 2 60 guanfacine extended release 60 overactive bladder symptoms 60 Ischemic 60 Kinoid 60 Alequel 60 pathophysiological 60 stratifying patients 60 somatostatin analog 60 muscarinic 60 pathophysiological mechanisms 60 cMET 60 RISPERDAL ® 60 Carbamazepine 60 CGRP 60 inhibit platelet function 60 Parkinson Disease PD 60 Lisofylline 60 Parathyroid hormone 60 gastrointestinal motility 60 Silodosin 60 Diabetic neuropathy 60 VAPRISOL 60 treating neuropathic pain 60 SGPT 60 VA# [002] 60 adenosine A2A 60 AGTR1 60 opioid bowel dysfunction 60 mGluR2 positive 60 peripherally acting 60 agomelatine 60 ALB # 60 membranous nephropathy 60 Sipuleucel T 60 primidone 60 preclinically 60 gastro esophageal reflux 60 hepatotoxic 60 Tobias Kurth 60 Bosutinib 60 melatonin receptor 60 P#X# 60 Fingolimod 60 Cardiotoxicity 60 PYY #-# 60 Darapladib 60 SSc 60 endocannabinoid signaling 60 interleukin IL -# 60 rheumatoid arthritis osteoarthritis ankylosing 60 constipation predominant irritable bowel 60 prostate carcinogenesis 59 ExTRACT TIMI 59 ONCONASE R 59 selective agonists 59 Angiotensin Converting Enzyme 59 Pharmacokinetic studies 59 Atomoxetine 59 PPARgamma 59 Selective serotonin reuptake inhibitors 59 5 HT2A 59 gastro esophageal reflux disease 59 CTEPH 59 Lu AA# 59 K ras mutations 59 galanin 59 euthymic patients 59 pleiotropic 59 Interferon Beta 59 Heterozygous Familial Hypercholesterolemia 59 Akathisia 59 Inhibitory 59 alpha#beta# integrin 59 CETP inhibition 59 CIPN 59 immunomodulatory agents 59 Catheter Associated 59 p# inhibitor 59 Rasagiline 59 hypogonadotropic hypogonadism 59 SUSTENNA TM 59 chromium supplementation 59 neuroregenerative 59 Overactive Bladder 59 neuronal plasticity 59 clevidipine 59 neuroinflammatory diseases 59 hyperglycaemia 59 potentiation 59 Tyrima 59 pediatric malignancies 59 medically refractory 59 primary hyperparathyroidism 59 PKC# 59 dopamine D2 59 Teriparatide 59 Aurora Kinase 59 Hypothalamic 59 IL6 59 dopaminergic 59 DHEA supplementation 59 Incretin 59 Hypertriglyceridemia 59 partial agonist 59 amyloid deposition 59 Cholinesterase inhibitors 59 diabetic polyneuropathy 59 Akt inhibitor 59 generalized anxiety disorder GAD 59 Lixivaptan 59 Elocalcitol 59 #ME# 59 benign prostatic hypertrophy BPH 59 vaso occlusive crisis 59 PKC inhibitors 59 Pimavanserin 59 γ secretase 59 Non inferiority 59 urate oxidase 59 CG# [003] 59 Denufosol 59 hypereosinophilic syndrome 59 intracoronary 59 clinicopathological 59 neuronal dysfunction 59 Cardiopulmonary bypass 59 florbetaben 59 Sudhir Agrawal D.Phil 59 irreversible inhibitor 59 nucleoside analog 59 angiogenesis inhibition 59 antitumor efficacy 59 glucose abnormalities 59 imexon 59 reflux esophagitis 59 Diastolic Heart Failure 59 pharmacological chaperone 59 CYT# QbG# 59 c myc gene 59 Virulizin ® 59 antiapoptotic 59 neuro protective 59 RezularTM 59 NK1 59 antiarrhythmic 59 beta 1a 59 chronic eosinophilic leukemia 59 endophenotypes 59 antiproliferative effects 59 chronic thromboembolic pulmonary 59 acadesine 59 CYP#A# CYP#D# 59 circadian rhythm disorders 59 plasma kallikrein 59 kidney urologic 59 estrogen receptor beta 59 #F FDG PET 59 pharmacologic approaches 59 HMG CoA reductase inhibitors 59 chronic myocardial ischemia 59 CB2 receptor 59 VMAT2 59 insulin sensitizing 59 noradrenergic 59 Glucocorticoid 59 Etanercept 59 chronic prostatitis chronic 59 metastatic neuroendocrine tumors 59 neuroactive 59 hyperphenylalaninemia HPA due 59 Tasigna prolongs 59 Electroencephalography 59 antifibrotic 59 familial hypercholesterolemia FH 59 anti fibrotic 59 diabetes mellitus DM 59 pharmacologic intervention 59 modulatory 59 See CLINICAL PHARMACOLOGY 59 GH deficiency 59 quetiapine Seroquel 59 EoE 59 Dissociation 59 leukotriene receptor antagonists 59 selective agonist 59 experimental allergic encephalomyelitis 59 GRN# 59 cervicitis 59 pharmacologic treatments 59 alagebrium 59 antiresorptive 59 Certolizumab pegol 59 LT NS# 59 β blockers 58 pharmacodynamic properties 58 Factor VIIa 58 Aflibercept 58 hyperparathyroidism 58 antiplatelet medications 58 idiopathic PAH 58 DHFR 58 LPA1 58 NK1R 58 Haptoglobin 58 dual endothelin receptor antagonist 58 Mg Uk 58 Diabetic nephropathy 58 Systemic lupus erythematosus SLE 58 2A receptor agonist 58 Microalbuminuria 58 mGluR2 58 fatty acid synthase 58 thienopyridines 58 plasma pharmacokinetics 58 Magnesium deficiency 58 biologic plausibility 58 R roscovitine 58 CYP#D# inhibitor 58 prognostic biomarker 58 CCR2 58 mTOR signaling 58 Pegylated 58 Zollinger Ellison Syndrome 58 Nonspecific 58 primary aldosteronism 58 Disease Progression 58 neuronal signaling 58 Temsirolimus 58 Effexor venlafaxine 58 fosbretabulin 58 orally inhaled migraine 58 noninfectious uveitis 58 neuroinflammatory 58 Peripheral Arterial 58 mTOR signaling pathway 58 immunomodulatory therapy 58 diabetic kidney 58 tumorigenicity 58 intestinal microbiota 58 BRAF V#E 58 AGILECT R 58 Hypoactive Sexual Desire Disorder 58 Squalamine 58 soluble tumor necrosis 58 calcitonin gene related 58 PDE4 inhibitor 58 cardiogenic 58 highly selective inhibitor 58 Angiotensin converting enzyme 58 artery stenosis 58 HuMax EGFr 58 postprandial hyperglycemia 58 glucocorticoid receptors 58 antioxidant supplementation 58 HIF 1alpha 58 amylin 58 Diabetic Foot Ulcer 58 prognostic significance 58 nonpharmacologic 58 Valproic acid 58 mTOR mammalian target 58 diabetes dyslipidemia 58 Aeolus Pharmaceuticals Announces 58 muscarinic receptors 58 prognostic indicator 58 vasoactive 58 TCF#L# 58 infantile colic 58 benfotiamine 58 Meets Primary Endpoint 58 mineralocorticoid receptor 58 KRAS mutation status 58 LRP5 58 somatostatin 58 Antitumor Activity 58 Malignant Glioma 58 thiopurine 58 Gleevec inhibits 58 hypothalamic pituitary adrenal axis 58 GABA neurotransmitter 58 constipation predominant IBS 58 endotoxemia 58 Glucocorticoids 58 obstructive sleep apnea hypopnea 58 Carvedilol 58 torsade de pointes 58 acute mania 58 mertansine 58 agonism 58 NAVISTAR R 58 mTOR inhibition 58 activate AMPK 58 metaplasia 58 extramedullary 58 hyperprolactinemia 58 antidepressant efficacy 58 prucalopride 58 Guanfacine 58 nonalcoholic steatohepatitis NASH 58 Ziprasidone 58 diabetic gastroparesis 58 metastatic malignant 58 biliary tract cancer 58 chemokine receptor 58 inhibiting mTOR 58 diarrhea predominant irritable 58 flecainide 58 antiphospholipid antibodies 58 CDK inhibitor 58 murine model 58 vWF 58 5HT 58 receptor blocker 58 myeloproliferative 58 REMINYL ® 58 antibody mediated 58 Degenerative Disc Disease 58 Anavex #-# 58 Aviptadil 58 kallikrein 58 thalidomide Thalomid 58 statins cholesterol lowering 58 nicotinic acetylcholine receptors 58 SGS# 58 pouchitis 58 Factor Receptor 58 occlusive disease 58 pulmonary hypertension PH 58 MELAS 58 Treg cell 58 small molecule activators 58 Topiramate 58 Myelination 58 SIADH 58 Generalised Anxiety Disorder 58 D aspartate NMDA receptor 58 PEDF 58 NIDDM 58 cholesterol homeostasis 58 TrkA 58 aripiprazole Abilify 58 OSAHS 58 Androgen Receptor 58 cortical stimulation 58 atheromatous 58 atherogenesis 58 poststroke depression 58 JAK2 Inhibitor 58 Granulocyte Colony Stimulating Factor 58 comorbid depression 58 CEACAM1 58 lowering blood glucose 58 cardiac fibrosis 58 Hypercholesterolemia 58 overt hypothyroidism 58 Endothelin 58 Fatty liver 58 brivaracetam 58 INVEGA ™ 58 canakinumab 58 serotonin reuptake inhibitor 58 extracellular dopamine 58 Pseudomonas aeruginosa infections 58 IGFBP2 58 Interstitial cystitis 58 node metastases 58 Lipsovir ® 58 mGlu2 3 58 Pagoclone 58 MVA MUC1 IL2 58 thyrotropin 58 Perforomist ™ Inhalation Solution 58 primary dysmenorrhea 58 FGFs 58 Cognitive behavioral therapy 58 choroidal neovascularization 58 Urinary tract 58 lipoprotein metabolism 58 Vimpat R 58 Cytotoxic T 58 penile fibrosis 58 Amino acid 58 EGFR signaling 58 Cariprazine 58 Nilotinib 58 androgen receptor AR 58 Detrol Detrol LA 58 cannabinoid receptor 58 cardiac contractility 58 JAK2 enzyme 58 GBA mutations 58 impaired glucose metabolism 58 comorbid anxiety 58 Fc fusion protein 58 norepinephrine transporter 58 dose dependently 58 pharmacotherapeutic 58 esophageal reflux 58 opioid induced 58 EFFEXOR XR 58 Epidermal Growth Factor Receptor 58 Panzem R 58 Obsessive compulsive disorder OCD 58 nociceptive pain 58 oral anticoagulation 58 TNF Tumor Necrosis Factor 58 kinase inhibition 58 heparin induced thrombocytopenia 58 dyskinesia PD LID 58 cell adhesion molecule 58 prostatic tissue 58 hMG 58 ATACAND 58 variceal bleeding 58 synovial cells 58 ischemia induced 58 SPRIX ® 58 Fulvestrant 58 Diagnostic Criteria 58 Dysregulation 58 preoperative diagnosis 58 Tranexamic acid 58 ADPKD 58 APOE genotype 58 Parkinsonian 58 mTOR kinase 58 predisposing factor 58 Symadex 58 Aortic stenosis 58 Golimumab 58 JAK2 inhibitor 58 5 HT2A serotonin 58 potent antiproliferative 58 STAT3 signaling 58 intranasal corticosteroids 58 IL 1ß 58 Tiotropium 58 tranylcypromine 58 inflammatory demyelinating 58 secondary hyperparathyroidism 58 post herpetic 58 molecular mimicry 58 Akt activation 58 lysophosphatidic acid LPA 57 Diabetic Neuropathy 57 systolic hypertension 57 airway remodeling 57 Treating Chronic 57 abacavir Ziagen 57 proteoglycan 57 chronic idiopathic thrombocytopenic purpura 57 pathological hallmarks 57 electroencephalographic 57 NKX#.# 57 Tasimelteon 57 endogenous cannabinoid 57 immunomodulatory effects 57 bronchial hyperresponsiveness 57 eotaxin 57 anti amnesic 57 Capesaris 57 vanilloid receptor 57 GnRH analogues 57 Decitabine 57 leiomyomas 57 CCR9 antagonist 57 targeting CD# 57 polycystin 1 57 Hedgehog inhibitor 57 anthracycline chemotherapy 57 peptide CGRP 57 inflammatory bowel syndrome 57 Ileus 57 probiotic supplementation 57 Gleevec resistant 57 postoperative delirium 57 Vidofludimus 57 nicotinic receptor 57 AZILECT ® 57 pharmacological therapies 57 gastrointestinal dysfunction 57 Restless legs 57 Lamotrigine 57 citicoline 57 lumiliximab 57 inducible nitric oxide synthase 57 gene polymorphism 57 arginine vasopressin AVP 57 class mGluR5 inhibitor 57 SIBO 57 Hydroxyurea 57 Upregulation 57 sacral nerve stimulation 57 5 HT4 receptor 57 oral prodrug 57 Estrogen Receptor 57 interstitial cystitis IC 57 Intravenous immunoglobulin 57 Prolactin 57 papillary thyroid carcinoma 57 NOD mouse 57 aetiological 57 p# MAPK 57 Mipomersen 57 dissolving blood clots 57 gamma secretase inhibitor 57 STRATEGY FOR AN OPEN 57 mu opioid 57 Adult Stem Cell Therapy 57 NMES 57 BYSTOLIC 57 Adjuvant chemotherapy 57 Subclinical 57 induce orthostatic hypotension 57 nonhuman primate model 57 Accumulating evidence 57 aurora kinase 57 Spasticity 57 Pitavastatin 57 Multiple Ascending Dose 57 serotonin receptor 57 Dasatinib 57 acting inhaled anticholinergic 57 axonal damage 57 phenothiazines 57 transabdominal 57 aberrant activation 57 M. catarrhalis 57 Pharmacological 57 5 hydroxytryptamine 57 apoptosis induced 57 Immunotherapeutic 57 CRF antagonists 57 colorectal carcinoma 57 left ventricular diastolic 57 either acutely decompensated 57 Acute Renal Failure 57 neovascularisation 57 fast skeletal troponin 57 mu opioid receptor antagonist 57 Simulect 57 Talabostat 57 LAB CGRP 57 Clinical Relevance 57 gene polymorphisms 57 pharmacologic 57 pentoxifylline 57 immune reconstitution syndrome 57 anti dyslipidemic 57 Modrenal 57 HeFH 57 endothelin receptor 57 MEVACOR 57 aetiology 57 recurrent glioblastoma multiforme 57 Hsp# chaperone 57 PLX STROKE targeting 57 Antithrombin 57 multicentric 57 Liver transplantation 57 abnormal p# 57 CB1 antagonists 57 STAT3 activation 57 neurobiological underpinnings 57 Natalizumab 57 immunomodulatory properties 57 BPS IC 57 NSAID induced 57 Nesiritide 57 autoimmune encephalitis 57 WNK1 57 Abatacept 57 reslizumab 57 potent inducer 57 Receptor Antagonists 57 visilizumab 57 Ranolazine 57 Angiolix 57 neuronal degeneration 57 delipidation 57 teratogenicity 57 indibulin 57 monogenic 57 Nalmefene 57 immune modulatory 57 prospective multicentre 57 amyloid plaque formation 57 neuroinflammation 57 dopamine antagonists 57 SGLT 2 57 Hutchinson Gilford progeria 57 Deforolimus 57 psoriasis Crohn disease 57 ACV1 57 NRG1 57 Smoothened 57 Mutational 57 PEGylated anti 57 idiopathic thrombocytopenic purpura 57 Escitalopram 57 Idiopathic 57 INTEGRILIN R 57 epigenetic therapies 57 Rotigotine 57 NR2B 57 dysregulated 57 HuLuc# 57 HIV HCV coinfected 57 debilitating neurodegenerative disorder 57 selectively inhibited 57 GRNCM1 57 Neuroprotection 57 periprocedural MI 57 LHRH antagonists 57 GSK3B 57 alexithymia 57 Atopic dermatitis 57 FASLODEX 57 cAMP signaling 57 Archexin 57 Iloperidone 57 Guanilib 57 thrombin receptor 57 Thyroid hormone 57 Exelixis XL# 57 cardiac conduction 57 noninvasive outpatient 57 Alpha lipoic acid 57 Vernakalant 57 nonmetastatic 57 mGluR4 57 Dapagliflozin 57 hypercalcemia 57 Retinoic Acid 57 mediated apoptosis 57 neurocognitive deficits 57 myeloproliferative diseases 57 transgenic mouse models 57 fatty acid amide hydrolase 57 PPAR gamma agonists 57 hypometabolism 57 Triptans 57 glutamate neurotransmission 57 GATA3 57 RAV# 57 secondary amenorrhea 57 acamprosate 57 sunitinib Sutent 57 glucocorticoid receptor 57 Pyridorin 57 CP CPPS 57 neuronal nitric oxide synthase 57 Irritable Bowel 57 mecamylamine 57 SLC#A# [002] 57 Helicobacter pylori infection 57 clinically meaningful reductions 57 vivo validation 57 hyperinsulinism 57 allergic inflammation 57 SCN9A 57 subsyndromal 57 subthalamic nucleus STN 57 migraine prophylaxis 57 colon carcinogenesis 57 neurofibrillary 57 H2 antagonists 57 selective adenosine 57 colorectal adenocarcinoma 57 Benign Prostatic Hyperplasia 57 Rilonacept 57 electrophysiologic 57 arteriography 57 oral ghrelin agonist 57 Electroconvulsive therapy 57 podocyte 57 gonadotrophin releasing hormone 57 T2DM 57 ERK1 2 57 anti Parkinsonian 57 IPAH 57 Genetic predisposition 57 BARI 2D 57 hippocampal neurogenesis 57 tricyclic antidepressants TCAs 57 immunomodulation 57 5alpha reductase 57 M1 muscarinic 57 histone deacetylase inhibitor 57 LPS induced 57 oral Janus kinase 57 Chronic pancreatitis 57 Chemotherapy induced 57 calcium calmodulin dependent 57 T1DM 57 antiinflammatory 57 DNA methylation patterns 57 activating dopamine receptors 57 headache abdominal pain 57 bacterial prostatitis 57 CCX# B 57 neuritic 57 PDE4 inhibitors 57 etiologic factors 57 genetic polymorphisms 57 D aspartic acid 57 post operative ileus 57 fulvestrant 57 hyperplasia BPH 57 Genetic variants 57 NMDA N 57 Interpersonal psychotherapy 57 icatibant 57 Hepatotoxicity 57 vascular disrupting agents 57 reflux disease GERD 57 adenosine receptors 57 endothelial nitric oxide 57 visceral metastases 57 Bifeprunox 57 cisplatin resistant 57 growth hormone secretion 57 immunoregulatory 57 neuroprotective agent 57 peptide hormone 57 ® pioglitazone HCl 57 Chronic Heart Failure 57 BCL#A 57 ULORIC 57 Removab 57 Homeostasis 57 coagulopathy 57 cardiovascular morbidity 57 potentially modifiable 57 carotid atherosclerosis 57 RhuDex R 57 methyl D aspartate 57 CSF biomarkers 57 CYP#A# substrate 57 Duodenal 57 AA Amyloidosis 57 bronchoalveolar lavage 57 colorectal adenoma 57 acid suppressive therapy 57 PEGylated Fab fragment 57 Chlamydia pneumoniae 57 eprotirome 57 midstage clinical 57 gastric adenocarcinoma 57 HPA axis 57 IFN γ 57 #:#-#,# CrossRef Medline [001] 57 Muraglitazar 57 natriuretic 57 tumor necrosis 57 small molecule tyrosine 57 CCR9 57 Anti Tumor 57 carcinoembryonic antigen 57 emotional lability 57 pathophysiology 57 investigational humanized monoclonal antibody 57 ergot alkaloids 57 levocetirizine 57 Microplasmin 57 Phase 2a Clinical Trial 57 osteogenic differentiation 57 5 HT1A 57 MyoCell SDF 1 57 potent suppressor 57 Percutaneous Tibial Nerve Stimulation 57 p#/CBP 57 HIF PH 57 #HT#A 56 immune modulating 56 dose proportionality 56 hyperammonemia 56 E#F# 56 gastric cardia 56 DNA hypermethylation 56 Hypotension 56 pancreatic endocrine 56 serotonergic 56 vaginal candidiasis 56 Panzem 56 INVEGA ® 56 sodium glucose cotransporter 56 recurrent herpes labialis 56 schizophrenia CIAS 56 oncogenic signaling 56 Fenretinide 56 Lymph node 56 CagA 56 metabolomic profiles 56 nonalcoholic steatohepatitis 56 bexarotene 56 antiangiogenic 56 varenicline Chantix 56 antidiabetic 56 Zolpimist ™ 56 mitogenic 56 metabolic dysfunction 56 idiopathic myelofibrosis 56 serotonin reuptake 56 presymptomatic 56 FGFR4 56 5 HT2C 56 coadministration 56 myocardial infarct size 56 leptin receptor 56 anxiolytic 56 flavopiridol 56 orexin receptors 56 Alzheimer disease cognitive impairment 56 R lenalidomide 56 ABCB1 56 trial evaluating PRX# 56 somatostatin analogs 56 thromboembolism 56 factor TNF receptor 56 Oral Fingolimod 56 adrenocorticotropic hormone 56 V2 receptor 56 angiographically 56 neurogenic bladder 56 JAK inhibitors 56 TGFβ 56 denervation 56 Bosentan 56 neurokinin 1 56 motilin 56 Psychodynamic 56 refractory colorectal cancer 56 Patellofemoral 56 inhibitory receptor 56 P#X# receptor 56 hypercholesterolemia 56 topical calcineurin inhibitors 56 endoplasmic reticulum stress 56 delayed gastric emptying 56 progressive neurodegenerative disorder 56 nNOS 56 neurohormonal 56 NKG2D 56 CaPre TM 56 bronchodilatory 56 DFMO 56 Aggrastat ® tirofiban hydrochloride 56 Cimzia TM 56 neurologic disorder 56 pharmacokinetic interactions 56 vivo coagulation 56 EXJADE 56 esophagogastric 56 AFREZZA TM 56 gastric carcinogenesis 56 chronic prostatitis 56 Ambrisentan 56 Aripiprazole 56 erythropoietic 56 tryptophan depletion 56 HCV replication 56 Zoraxel 56 Laquinimod 56 PPAR agonist 56 Orally administered 56 Schizoaffective Disorder 56 tegaserod 56 sorafenib Nexavar 56 intestinal permeability 56 PDE# 56 antiangiogenic therapy